PL3983064T3 - Modulatory cot i sposoby ich zastosowania - Google Patents
Modulatory cot i sposoby ich zastosowaniaInfo
- Publication number
- PL3983064T3 PL3983064T3 PL20751726.9T PL20751726T PL3983064T3 PL 3983064 T3 PL3983064 T3 PL 3983064T3 PL 20751726 T PL20751726 T PL 20751726T PL 3983064 T3 PL3983064 T3 PL 3983064T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- cot
- modulators
- cot modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861390P | 2019-06-14 | 2019-06-14 | |
| PCT/US2020/037214 WO2020252151A1 (en) | 2019-06-14 | 2020-06-11 | Cot modulators and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3983064T3 true PL3983064T3 (pl) | 2024-06-24 |
Family
ID=71950735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20751726.9T PL3983064T3 (pl) | 2019-06-14 | 2020-06-11 | Modulatory cot i sposoby ich zastosowania |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US20210061831A1 (pl) |
| EP (2) | EP3983064B1 (pl) |
| JP (4) | JP7286813B2 (pl) |
| KR (3) | KR102714138B1 (pl) |
| CN (3) | CN114026104B (pl) |
| AR (1) | AR119138A1 (pl) |
| AU (3) | AU2020290461B2 (pl) |
| BR (1) | BR112021025039A2 (pl) |
| CA (1) | CA3142478A1 (pl) |
| CL (2) | CL2021003336A1 (pl) |
| CO (1) | CO2021016834A2 (pl) |
| CR (1) | CR20210620A (pl) |
| DK (1) | DK3983064T3 (pl) |
| DO (1) | DOP2023000172A (pl) |
| ES (1) | ES2978687T3 (pl) |
| FI (1) | FI3983064T3 (pl) |
| HR (1) | HRP20240351T1 (pl) |
| HU (1) | HUE066717T2 (pl) |
| IL (4) | IL311531A (pl) |
| LT (1) | LT3983064T (pl) |
| MX (2) | MX2021015545A (pl) |
| PE (1) | PE20220509A1 (pl) |
| PH (1) | PH12021553010A1 (pl) |
| PL (1) | PL3983064T3 (pl) |
| PT (1) | PT3983064T (pl) |
| SG (1) | SG11202113307TA (pl) |
| SI (1) | SI3983064T1 (pl) |
| TW (1) | TWI770527B (pl) |
| UA (1) | UA128242C2 (pl) |
| WO (1) | WO2020252151A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101974793B1 (ko) | 2015-07-06 | 2019-05-02 | 길리애드 사이언시즈, 인코포레이티드 | Cot 조정제 및 그의 사용 방법 |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| AU2021249010B2 (en) | 2020-03-30 | 2024-09-26 | Gilead Sciences, Inc. | Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| JP7446475B2 (ja) | 2020-04-02 | 2024-03-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｏｔ阻害剤化合物を調製するためのプロセス |
| TW202304435A (zh) * | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療ｎａｓｈ之方法 |
| EP4359401A1 (en) * | 2021-06-23 | 2024-05-01 | Blueprint Medicines Corporation | Process for preparing egfr inhibitors |
| US20240174702A1 (en) * | 2022-05-12 | 2024-05-30 | Gilead Sciences, Inc. | Solid forms of a compound for modulating cot |
| WO2024182811A1 (en) * | 2023-03-02 | 2024-09-06 | University Of South Florida | Compositions and methods for treating uterine leiomyomas |
| WO2024245157A1 (zh) * | 2023-05-30 | 2024-12-05 | 浙江星浩澎博医药有限公司 | 氮杂喹啉环衍生物 |
| TW202523303A (zh) | 2023-12-11 | 2025-06-16 | 美商基利科學股份有限公司 | 用於治療發炎性腸道疾病之化合物及方法 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3930837A (en) | 1971-12-31 | 1976-01-06 | Ici Australia Limited | 3-chloro-5-acetamidaisoquinoline as a herbicide |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| NL7800191A (nl) | 1977-01-10 | 1978-07-12 | Ciba Geigy | Anthelmintisch preparaat. |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP2634438B2 (ja) | 1988-07-26 | 1997-07-23 | 三井東圧化学株式会社 | 不斉ビスオキサゾリルピリジン誘導体およびその製造方法 |
| DE4014171A1 (de) | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
| GB9310700D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Novel composition |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| AU734678B2 (en) | 1997-08-28 | 2001-06-21 | Nissan Chemical Industries Ltd. | Industrial antibacterial and antifungal agents, algicides and agents for preventing adhesion of organisms containing a cyanoacrylate compound |
| EP1097158B1 (en) | 1998-07-10 | 2006-01-25 | Massachusetts Institute Of Technology | Ligands for metals and metal-catalyzed processes |
| BR9914164A (pt) | 1998-09-29 | 2001-06-26 | American Cyanamid Co | Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto |
| HRP20040853A2 (en) | 2002-03-20 | 2004-12-31 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| PL378754A1 (pl) | 2003-03-03 | 2006-05-15 | F.Hoffmann-La Roche Ag | 2,5- i 2,6-Podstawione tetrahydroizochinoliny do stosowania jako modulatory 5-HT6 |
| AU2004267061A1 (en) | 2003-08-19 | 2005-03-03 | Wyeth Holdings Corporation | Process for the preparation of 4-amino-3-quinolinecarbonitriles |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| TW200529846A (en) | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006124944A1 (en) | 2005-05-18 | 2006-11-23 | Wyeth | 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same |
| BRPI0609928A2 (pt) | 2005-05-18 | 2010-05-11 | Wyeth Corp | inibidores de quinase tpl-2 de 3-cianoquinolina e métodos de fabricação e uso dos mesmos |
| GT200600228A (es) | 2005-05-27 | 2006-12-26 | Inhibidores de la fosfolipasa a2 citosolica | |
| TW200819441A (en) | 2005-10-28 | 2008-05-01 | Abbott Lab | Prodrugs of compounds that inhibit TRPV1 receptor |
| JP5255559B2 (ja) | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
| JP5599614B2 (ja) | 2006-11-09 | 2014-10-01 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| WO2008092292A1 (en) | 2007-01-17 | 2008-08-07 | The Hong Kong University Of Science And Technology | Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2 |
| FR2919286A1 (fr) | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| GB0820856D0 (en) | 2008-11-14 | 2008-12-24 | Univ Leuven Kath | Novel inhibitors of flavivirus replication |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| GB0922302D0 (en) | 2009-12-22 | 2010-02-03 | Imp Innovations Ltd | Compounds |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| EP2581372B1 (en) | 2010-06-09 | 2017-06-07 | Tianjin Hemay Oncology Pharmaceutical Co., Ltd. | Cyanoquinoline derivatives |
| JP6110787B2 (ja) | 2011-05-10 | 2017-04-05 | 協和発酵キリン株式会社 | ピリミドジアゼピノン化合物 |
| EP2729007A1 (de) | 2011-07-04 | 2014-05-14 | Bayer Intellectual Property GmbH | Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| PL2772482T3 (pl) | 2011-10-27 | 2016-08-31 | Taisho Pharmaceutical Co Ltd | Pochodna azolu |
| LT2776038T (lt) | 2011-11-11 | 2018-04-25 | Gilead Apollo, Llc | Acc inhibitoriai ir jų panaudojimas |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| CN103483363B (zh) | 2012-06-13 | 2016-12-21 | 上海赛迦化工产品有限公司 | 多样性的手性氨基硼酸及其制备方法和应用 |
| WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
| CN103408572B (zh) | 2013-07-12 | 2015-12-02 | 上海工程技术大学 | 手性氨基硼酸衍生物及其制备方法和应用 |
| WO2015070366A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| CN108947867A (zh) | 2013-12-12 | 2018-12-07 | 卡利拉制药公司 | 双环烷基化合物及合成 |
| CA2942144C (en) | 2014-03-07 | 2023-08-22 | Kalyra Pharmaceuticals, Inc. | Propellane derivates and synthesis |
| WO2016007966A2 (en) | 2014-07-11 | 2016-01-14 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
| CN106999451B (zh) | 2014-09-17 | 2021-04-02 | 里科瑞尔姆Ip控股有限责任公司 | 双环化合物 |
| EP3197448B1 (en) | 2014-09-24 | 2019-04-24 | Gilead Sciences, Inc. | Methods of treating liver disease |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| TWI685491B (zh) | 2014-12-23 | 2020-02-21 | 美商基利科學股份有限公司 | 製備５-（４-環丙基-１ｈ-咪唑-１-基）-ｎ-（６-（４-異丙基-４ｈ-１,２,４-三唑-３-基）吡啶-２-基）-２-氟-４-甲基苯甲醯胺之方法 |
| JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| KR102205143B1 (ko) | 2015-01-16 | 2021-01-21 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 그리드 결과를 개선하기 위해 그리드 액션을 선택하기 위한 시스템 및 방법 |
| EP3319955B1 (en) | 2015-07-06 | 2020-11-25 | Gilead Sciences, Inc. | 6-amino-quinoline-3-carbonitrils as cot modulators |
| KR101974793B1 (ko) | 2015-07-06 | 2019-05-02 | 길리애드 사이언시즈, 인코포레이티드 | Cot 조정제 및 그의 사용 방법 |
| ES2920888T3 (es) | 2015-12-31 | 2022-08-11 | Hitgen Inc | Derivado de sulfonamida y método de preparación y uso del mismo |
| CN119977993A (zh) | 2016-03-02 | 2025-05-13 | 吉利德阿波罗公司 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| EP3473715B1 (en) | 2016-06-21 | 2021-08-04 | PHC Holdings Corporation | Catalase inhibitor and method for measuring analyte using catalase inhibitor |
| EP3478674B1 (en) * | 2016-06-30 | 2020-05-13 | Gilead Sciences, Inc. | 4,6-diaminoquinazolines as cot modulators and methods of use thereof |
| CN106512014A (zh) | 2016-10-27 | 2017-03-22 | 武汉大学 | 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 |
| EP4273132A3 (en) | 2017-03-03 | 2024-01-10 | Gilead Sciences, Inc. | Processes for preparing acc inhibitors and solid forms thereof |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| AU2018250614A1 (en) | 2017-04-12 | 2019-10-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| KR102419458B1 (ko) | 2017-10-06 | 2022-07-12 | 길리애드 사이언시즈, 인코포레이티드 | Acc 억제제를 포함하는 조합 요법 |
| CN108636625B (zh) * | 2018-03-13 | 2021-09-14 | 因诺弥斯特有限责任公司 | 多模式流体喷嘴 |
| CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CN109928956B (zh) | 2019-02-27 | 2020-10-13 | 杭州偶联医药科技有限公司 | 一种靶向泛素化降解egfr蛋白的化合物及其药物组合物和应用 |
| WO2020185685A1 (en) | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating acne |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| AU2021249010B2 (en) | 2020-03-30 | 2024-09-26 | Gilead Sciences, Inc. | Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| JP7446475B2 (ja) | 2020-04-02 | 2024-03-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｏｔ阻害剤化合物を調製するためのプロセス |
| CN112300072A (zh) | 2020-10-14 | 2021-02-02 | 常州工学院 | 5-碘异喹啉类化合物的高收率合成方法 |
| TW202304435A (zh) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療ｎａｓｈ之方法 |
| US20240174702A1 (en) | 2022-05-12 | 2024-05-30 | Gilead Sciences, Inc. | Solid forms of a compound for modulating cot |
-
2020
- 2020-06-10 TW TW109119416A patent/TWI770527B/zh active
- 2020-06-11 MX MX2021015545A patent/MX2021015545A/es unknown
- 2020-06-11 SG SG11202113307TA patent/SG11202113307TA/en unknown
- 2020-06-11 EP EP20751726.9A patent/EP3983064B1/en active Active
- 2020-06-11 US US16/898,981 patent/US20210061831A1/en not_active Abandoned
- 2020-06-11 IL IL311531A patent/IL311531A/en unknown
- 2020-06-11 LT LTEPPCT/US2020/037214T patent/LT3983064T/lt unknown
- 2020-06-11 JP JP2021573842A patent/JP7286813B2/ja active Active
- 2020-06-11 KR KR1020237041219A patent/KR102714138B1/ko active Active
- 2020-06-11 SI SI202030398T patent/SI3983064T1/sl unknown
- 2020-06-11 CN CN202080043370.7A patent/CN114026104B/zh active Active
- 2020-06-11 PT PT207517269T patent/PT3983064T/pt unknown
- 2020-06-11 HR HRP20240351TT patent/HRP20240351T1/hr unknown
- 2020-06-11 PE PE2021002080A patent/PE20220509A1/es unknown
- 2020-06-11 AR ARP200101649A patent/AR119138A1/es unknown
- 2020-06-11 UA UAA202107612A patent/UA128242C2/uk unknown
- 2020-06-11 BR BR112021025039A patent/BR112021025039A2/pt unknown
- 2020-06-11 HU HUE20751726A patent/HUE066717T2/hu unknown
- 2020-06-11 US US17/618,696 patent/US20220259234A1/en not_active Abandoned
- 2020-06-11 CR CR20210620A patent/CR20210620A/es unknown
- 2020-06-11 ES ES20751726T patent/ES2978687T3/es active Active
- 2020-06-11 AU AU2020290461A patent/AU2020290461B2/en active Active
- 2020-06-11 IL IL299567A patent/IL299567B2/en unknown
- 2020-06-11 EP EP24154495.6A patent/EP4375279A3/en active Pending
- 2020-06-11 DK DK20751726.9T patent/DK3983064T3/da active
- 2020-06-11 FI FIEP20751726.9T patent/FI3983064T3/fi active
- 2020-06-11 KR KR1020227000961A patent/KR102609360B1/ko active Active
- 2020-06-11 CN CN202410099768.2A patent/CN117946166A/zh active Pending
- 2020-06-11 PH PH1/2021/553010A patent/PH12021553010A1/en unknown
- 2020-06-11 PL PL20751726.9T patent/PL3983064T3/pl unknown
- 2020-06-11 CN CN202410099826.1A patent/CN117946167A/zh active Pending
- 2020-06-11 KR KR1020247032775A patent/KR20240151860A/ko not_active Ceased
- 2020-06-11 CA CA3142478A patent/CA3142478A1/en active Pending
- 2020-06-11 WO PCT/US2020/037214 patent/WO2020252151A1/en not_active Ceased
- 2020-08-17 US US16/994,889 patent/US10947259B2/en active Active
-
2021
- 2021-01-29 US US17/162,754 patent/US11325930B2/en active Active
- 2021-11-22 IL IL288310A patent/IL288310A/en unknown
- 2021-12-13 CO CONC2021/0016834A patent/CO2021016834A2/es unknown
- 2021-12-13 CL CL2021003336A patent/CL2021003336A1/es unknown
- 2021-12-14 MX MX2025010745A patent/MX2025010745A/es unknown
-
2022
- 2022-04-07 US US17/715,366 patent/US11827662B2/en active Active
-
2023
- 2023-01-11 CL CL2023000112A patent/CL2023000112A1/es unknown
- 2023-03-27 JP JP2023049724A patent/JP7671796B2/ja active Active
- 2023-08-29 DO DO2023000172A patent/DOP2023000172A/es unknown
- 2023-09-28 US US18/374,108 patent/US12398160B2/en active Active
-
2024
- 2024-04-02 AU AU2024202085A patent/AU2024202085B2/en active Active
- 2024-09-06 JP JP2024153983A patent/JP7735505B2/ja active Active
-
2025
- 2025-07-10 US US19/264,926 patent/US20250333428A1/en active Pending
- 2025-08-27 JP JP2025141232A patent/JP2025170010A/ja active Pending
- 2025-09-18 IL IL323450A patent/IL323450A/en unknown
-
2026
- 2026-03-03 AU AU2026201593A patent/AU2026201593A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287720A (en) | modulators of thr-in the cell and methods of using them | |
| LT3983064T (lt) | Cot moduliatoriai ir jų panaudojimo būdai | |
| IL274568A (en) | COT modulators and methods of using them | |
| IL276788A (en) | Compounds with activity that causes iron-dependent cell death and methods of using them | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| SG11202112978WA (en) | Auto-injector and related methods of use | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL277963A (en) | Bicyclic carboxamides and methods of using them | |
| ZA202207188B (en) | Liquid tasimelteon formulations and methods of use thereof | |
| GB2615478B (en) | Therapeutic and prophylactic use of microorganisms | |
| IL276053A (en) | Therapeutic Gard and methods of its use | |
| ZA202108213B (en) | Klebsiella vaccine and methods of use | |
| EP3749691A4 (en) | ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE | |
| IL287829A (en) | Progranulin modulators and methods of using them | |
| GB201900741D0 (en) | Liver-specifc inducible prometers and methods of use thereof | |
| GB2589398B (en) | Compounds and methods of use | |
| IL274433A (en) | Fulvestrant formulations and methods of using them | |
| IL276792A (en) | Inhaler and methods for using it | |
| IL290548A (en) | Bacteria and methods of using them | |
| GB201908573D0 (en) | Compounds and methods of use | |
| HK40053358A (en) | Anellosomes and methods of use | |
| HK40045754A (en) | B7-h7-binding agents and methods of use thereof | |
| HK40055592A (en) | Catabodies and methods of use thereof | |
| GB201905100D0 (en) | Polypeptides and methods of use | |
| HK40043593A (en) | Imidazodiazepinediones and methods of use thereof |